Marker Therapeutics, Inc. (MRKR)
0.9466
-0.06
(-6.28%)
USD |
NASDAQ |
Oct 13, 16:00
0.9466
0.00 (0.00%)
After-Hours: 20:00
Marker Therapeutics Enterprise Value : 4.918M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 4.918M |
| October 09, 2026 | 4.277M |
| October 08, 2026 | 3.917M |
| October 07, 2026 | 5.418M |
| October 06, 2026 | 4.918M |
| October 05, 2026 | 5.751M |
| October 02, 2026 | 5.584M |
| October 01, 2026 | 5.584M |
| September 30, 2026 | 5.918M |
| September 29, 2026 | 6.418M |
| September 28, 2026 | 6.835M |
| September 25, 2026 | 7.252M |
| September 24, 2026 | 7.919M |
| September 23, 2026 | 8.752M |
| September 22, 2026 | 8.419M |
| September 21, 2026 | 8.085M |
| September 18, 2026 | 7.752M |
| September 17, 2026 | 7.752M |
| September 16, 2026 | 7.085M |
| September 15, 2026 | 7.585M |
| September 14, 2026 | 7.585M |
| September 11, 2026 | 7.252M |
| September 10, 2026 | 8.085M |
| September 09, 2026 | 8.252M |
| September 08, 2026 | 9.419M |
| Date | Value |
|---|---|
| September 04, 2026 | 7.752M |
| September 03, 2026 | 8.752M |
| September 02, 2026 | 8.919M |
| September 01, 2026 | 9.753M |
| August 31, 2026 | 10.25M |
| August 28, 2026 | 10.92M |
| August 27, 2026 | 12.42M |
| August 26, 2026 | 12.25M |
| August 25, 2026 | 13.42M |
| August 24, 2026 | 13.09M |
| August 21, 2026 | 11.25M |
| August 20, 2026 | 8.419M |
| August 19, 2026 | 9.586M |
| August 18, 2026 | 7.252M |
| August 17, 2026 | 7.418M |
| August 14, 2026 | 7.085M |
| August 13, 2026 | 6.585M |
| August 12, 2026 | 7.418M |
| August 11, 2026 | 6.752M |
| August 10, 2026 | 7.252M |
| August 07, 2026 | 6.752M |
| August 06, 2026 | 6.752M |
| August 05, 2026 | 7.085M |
| August 04, 2026 | 8.586M |
| August 03, 2026 | 8.419M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.458B |
| Alnylam Pharmaceuticals, Inc. | 30.04B |
| Anika Therapeutics, Inc. | 260.79M |
| Savara, Inc. | 851.51M |
| Vericel Corp. | 2.011B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.826M |
| Total Expenses (Quarterly) | 1.826M |
| EPS Diluted (Quarterly) | -0.0946 |
| Earnings Yield | -50.78% |
| Normalized Earnings Yield | -50.77 |